Two series of 2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-carbonitriles 5a-h and 4-(4-chlorophenyl)-2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitriles 6a-h were synthesized via a cyclocondensation reaction of the corresponding 2-hydrazinopyrimidines 3a,b with the appropriate 2-propen-1-ones 4a-h. The target compounds were screened for their antiproliferative activity against A 549 (lung), HT 29 (colon), MCF 7 and MDA-MB 231 (breast) cell lines. The two most susceptible cell lines were the colon (HT 29) and breast (MDA-MB 231). Generally, the 4-unsubstitutedphenylpyrimidine derivatives 5a-h were more active than their 4-chlorophenylpyrimidine analogs 6a-h. Compounds 5e and 5g, showed high activity against three of the cell lines. The most active compound 5c possessed IC₅₀ = 1.76 μM against A 549 cell line.
Two series of 2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-4-phenyl-1,6-dihydropyrimidine-5-n class="Chemical">carbonitriles 5a-h and 4-(4-chlorophenyl)-2-(3,5-diaryl-4,5-dihydropyrazol-1-yl)-1-methyl-6-oxo-1,6-dihydropyrimidine-5-carbonitriles 6a-h were synthesized via a cyclocondensation reaction of the corresponding 2-hydrazinopyrimidines 3a,b with the appropriate 2-propen-1-ones 4a-h. The target compounds were screened for their antiproliferative activity against A 549 (lung), HT 29 (colon), MCF 7 and MDA-MB 231 (breast) cell lines. The two most susceptible cell lines were the colon (HT 29) and breast (MDA-MB 231). Generally, the 4-unsubstitutedphenylpyrimidine derivatives 5a-h were more active than their 4-chlorophenylpyrimidine analogs 6a-h. Compounds 5e and 5g, showed high activity against three of the cell lines. The most active compound 5c possessed IC₅₀ = 1.76 μM against A 549 cell line.
Authors: T D Penning; J J Talley; S R Bertenshaw; J S Carter; P W Collins; S Docter; M J Graneto; L F Lee; J W Malecha; J M Miyashiro; R S Rogers; D J Rogier; S S Yu; E G Burton; J N Cogburn; S A Gregory; C M Koboldt; W E Perkins; K Seibert; A W Veenhuizen; Y Y Zhang; P C Isakson Journal: J Med Chem Date: 1997-04-25 Impact factor: 7.446
Authors: G R Bebernitz; G Argentieri; B Battle; C Brennan; B Balkan; B F Burkey; M Eckhardt; J Gao; P Kapa; R J Strohschein; H F Schuster; M Wilson; D D Xu Journal: J Med Chem Date: 2001-08-02 Impact factor: 7.446
Authors: G C Rovnyak; S D Kimball; B Beyer; G Cucinotta; J D DiMarco; J Gougoutas; A Hedberg; M Malley; J P McCarthy; R Zhang Journal: J Med Chem Date: 1995-01-06 Impact factor: 7.446
Authors: J C Barrow; P G Nantermet; H G Selnick; K L Glass; K E Rittle; K F Gilbert; T G Steele; C F Homnick; R M Freidinger; R W Ransom; P Kling; D Reiss; T P Broten; T W Schorn; R S Chang; S S O'Malley; T V Olah; J D Ellis; A Barrish; K Kassahun; P Leppert; D Nagarathnam; C Forray Journal: J Med Chem Date: 2000-07-13 Impact factor: 7.446
Authors: S Manfredini; R Bazzanini; P G Baraldi; M Guarneri; D Simoni; M E Marongiu; A Pani; E Tramontano; P La Colla Journal: J Med Chem Date: 1992-03-06 Impact factor: 7.446
Authors: Ashraf H Abadi; Dalal A Abouel-Ella; Jochen Lehmann; Heather N Tinsley; Bernard D Gary; Gary A Piazza; Mohammed A O Abdel-Fattah Journal: Eur J Med Chem Date: 2009-09-20 Impact factor: 6.514